Joanne has more than 20 years of experience as a DMPK scientist and project manager gained at AstraZeneca. In this role, she led cross-functional teams to drive the optimal and efficient development of novel drugs. Joanne has worked across all therapy areas with a special expertise in oncology. Joanne brings a blend of scientific expertise and project management skills to optimise drug discovery and development processes.
Read more here Joanne Wilson
Stacey is an experienced customer facing professional programme manager with extensive experience in nurturing and establishing long-term relationships to ensure optimal delivery. She is an excellent communicator with the experience needed to manage complex projects with rapidly changing and competing priorities. A true customer advocate, Stacey brings calmness and clarity to provide the best service possible, eliciting and listening to feedback to improve outcomes.
Read more here Stacey Owen
Sarah is an experienced drug metabolism and pharmacokinetics (DMPK) consultant, having worked for almost 30 years in the pharmaceutical and CRO industries, providing a wide range of expertise to academia, biotechnology and pharmaceutical companies. A collaborative project leader, Sarah has broad experience ranging from lead identification though to end of Phase II clinical development. Sarah is passionate about making a difference to patients’ lives and delivering decision-making data to accelerate new drugs through the R&D pipeline.
Read more here Sarah Pass
PhD
Craig has extensive expertise in toxicology, discovery research, competitive intelligence and due diligence spanning more than three decades. He began his career at the Marion Merrell Dow research institute where he worked in Cardiovascular and CNS discovery before joining Eli Lilly in 1996 where he focused on increasing the efficiency and predictability of early phase safety assessment. Building on this, he spent two years leading cross-functional due diligence then progressed to lead strategic competitive intelligence for neuroscience, including conducting drug target assessments. Craig is passionate about the critical role toxicology plays in delivering innovative molecules with optimal risk-benefit profiles to address major unmet medical needs.
Read more here Dr Craig Thomas
Henry has a keen interest in economics and decided to acquire some business experience, joining ApconiX straight from sixth form college. Playing an active role within business development, Henry hopes to gain an understanding of how businesses become and remain successful before going on to study economics at university. An active mind and a willingness to take on new projects, Henry is well suited to the very busy, very demanding workload of a growing company.
Read more here Henry Bushell
MSc
Will studied for an integrated master’s degree in biomedical science at the University of Sheffield where he gained understanding of human health, disease processes and developed both practical and written skills. Particularly enjoying literature searches, critical reviews, data analysis and report writing, Will is keen to learn new skills as part of the target safety assessment team.
Read more here William Humfrey
MSc
With almost 20 years devoted to preclinical toxicology, Michelle has developed an excellent ability to conduct extensive literature searches, interrogating, analysing and interpreting data and has contributed to regulatory and scientific reports and produced numerous literature reviews. As a Senior Toxicologist, Michelle has experience of clinical chemistry, haematology, cytogenetics and conducting preclinical studies for clients globally. A collaborative and articulate communicator, Michelle has an aptitude for conveying complex scientific data in an accurate and concise manner.
Read more here Michelle Blissett
MSc
Scott has over 12 years’ experience at a UK CRO where he was Senior Toxicologist, Study Director, and manager of a team of study directors. As Senior Toxicologist, Scott advised clients on drug safety programs across multiple therapy areas and therapeutic modalities. This work included the design, conduct and reporting of nonclinical safety studies to support regulatory submissions. Scott has experience with agrochemical and chemical industry clients and the relevant regulatory guidelines including REACH. Collaborating with clients to obtain the best outcomes, Scott is easy to approach, always working to enable projects are completed in a timely manner.
Read more here Scott Hackford
PhD
Amy holds a PhD and Masters in Immunology and Cardiovascular science from the University of Sheffield. An experienced Immunologist with 10 years’ experience in non-clinical and clinical safety programme design for both biologic and small molecule compounds, Amy has led cross functional drug development teams globally within a large CRO. She has a strong reputation for building client relationships and managing projects and combines a passion for pharmaceutical development and fostering collaborative relationships.
Read more here Dr Amy Shepherd
PhD
Kerry is an experienced Project Manager with over 25 years’ experience in molecular toxicology, new target identification/validation and nonclinical safety within large pharmaceutical and biotech companies and contract research organisations. She has a strong background in driving complex, valuable, high profile drug development programmes. Kerry draws on her knowledge and passion for science in drug development to identity and solve problems with innovative thinking.
Read more here Dr Kerry Illston
